JP2022547809A5 - - Google Patents

Info

Publication number
JP2022547809A5
JP2022547809A5 JP2022510984A JP2022510984A JP2022547809A5 JP 2022547809 A5 JP2022547809 A5 JP 2022547809A5 JP 2022510984 A JP2022510984 A JP 2022510984A JP 2022510984 A JP2022510984 A JP 2022510984A JP 2022547809 A5 JP2022547809 A5 JP 2022547809A5
Authority
JP
Japan
Prior art keywords
amino acid
cell
acid sequence
cells
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022510984A
Other languages
English (en)
Japanese (ja)
Other versions
JP7737978B2 (ja
JP2022547809A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/047071 external-priority patent/WO2021034976A1/en
Publication of JP2022547809A publication Critical patent/JP2022547809A/ja
Publication of JP2022547809A5 publication Critical patent/JP2022547809A5/ja
Application granted granted Critical
Publication of JP7737978B2 publication Critical patent/JP7737978B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022510984A 2019-08-20 2020-08-19 Wt-1に特異的なt細胞免疫療法 Active JP7737978B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962889519P 2019-08-20 2019-08-20
US62/889,519 2019-08-20
PCT/US2020/047071 WO2021034976A1 (en) 2019-08-20 2020-08-19 T-cell immunotherapy specific for wt-1

Publications (3)

Publication Number Publication Date
JP2022547809A JP2022547809A (ja) 2022-11-16
JP2022547809A5 true JP2022547809A5 (https=) 2023-08-29
JP7737978B2 JP7737978B2 (ja) 2025-09-11

Family

ID=72473955

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022510984A Active JP7737978B2 (ja) 2019-08-20 2020-08-19 Wt-1に特異的なt細胞免疫療法

Country Status (9)

Country Link
US (1) US20220409661A1 (https=)
EP (1) EP4017872A1 (https=)
JP (1) JP7737978B2 (https=)
KR (1) KR20220050176A (https=)
CN (1) CN114555790B (https=)
AU (1) AU2020334064A1 (https=)
CA (1) CA3147717A1 (https=)
IL (1) IL290609A (https=)
WO (1) WO2021034976A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202406990D0 (en) * 2024-05-16 2024-07-03 Univ Oxford Innovation Ltd T cell receptors and uses thereof
WO2025245169A1 (en) 2024-05-21 2025-11-27 Fred Hutchinson Cancer Center Immunotherapy cells equipped with a collagen-targeting payload

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5420032A (en) 1991-12-23 1995-05-30 Universitge Laval Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
AU4932199A (en) 1998-07-31 2000-02-21 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product
AU2003215869B2 (en) 2002-03-15 2008-04-24 Cellectis Hybrid and single chain meganucleases and use thereof
WO2004024175A1 (ja) 2002-09-12 2004-03-25 Haruo Sugiyama 癌抗原ペプチド製剤
EP3202899B1 (en) 2003-01-28 2020-10-21 Cellectis Custom-made meganuclease and use thereof
GB0328363D0 (en) * 2003-12-06 2004-01-14 Imp College Innovations Ltd Therapeutically useful molecules
PT1731605E (pt) 2004-03-31 2010-04-14 Int Inst Cancer Immunology Inc Péptidos antigénicos de cancro derivados de wt1
JP2008527001A (ja) 2005-01-13 2008-07-24 ザ ジョンズ ホプキンス ユニバーシティー 前立腺幹細胞抗原ワクチンおよびその使用
ES2582091T3 (es) 2005-10-18 2016-09-09 Precision Biosciences Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas
US8119772B2 (en) 2006-09-29 2012-02-21 California Institute Of Technology MART-1 T cell receptors
EP2210903A1 (en) 2009-01-21 2010-07-28 Monoclonal Antibodies Therapeutics Anti-CD160 monoclonal antibodies and uses thereof
EP2258719A1 (en) 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Multiple target T cell receptor
US8586526B2 (en) 2010-05-17 2013-11-19 Sangamo Biosciences, Inc. DNA-binding proteins and uses thereof
US9676854B2 (en) 2011-08-15 2017-06-13 Medimmune, Llc Anti-B7-H4 antibodies and their uses
AU2013266968B2 (en) 2012-05-25 2017-06-29 Emmanuelle CHARPENTIER Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
US20140186843A1 (en) 2012-12-12 2014-07-03 Massachusetts Institute Of Technology Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
CA2894879A1 (en) 2012-12-19 2014-06-26 Amplimmune, Inc. B7-h4 specific antibodies, and compositions and methods of use thereof
CA2930877A1 (en) 2013-11-18 2015-05-21 Crispr Therapeutics Ag Crispr-cas system materials and methods
KR102415259B1 (ko) * 2013-11-22 2022-06-30 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 조작된 고-친화도의 인간 t 세포 수용체
US11390921B2 (en) * 2014-04-01 2022-07-19 Adaptive Biotechnologies Corporation Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs)
ES2841274T3 (es) * 2014-08-04 2021-07-07 Hutchinson Fred Cancer Res Inmunoterapia con células T específica para WT-1
WO2016040724A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
RU2017115315A (ru) 2014-10-03 2018-11-08 Дана-Фарбер Кэнсер Инститьют, Инк. Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
DK3653221T5 (da) 2015-02-19 2024-08-26 Compugen Ltd Anti-pvrig-antistoffer og anvendelsesfremgangsmåder
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
JP2019515656A (ja) * 2016-03-15 2019-06-13 キャンサー・リサーチ・テクノロジー・リミテッドCancer Research Technology Limited キメラ抗原受容体
CN109996868A (zh) 2016-09-23 2019-07-09 弗雷德哈钦森癌症研究中心 特异性用于次要组织相容性(h)抗原ha-1的tcr及其用途
WO2019178427A1 (en) 2018-03-14 2019-09-19 Arbor Biotechnologies, Inc. Novel crispr dna targeting enzymes and systems

Similar Documents

Publication Publication Date Title
US11932700B2 (en) Use of chimeric antigen receptor modified cells to treat cancer
Marofi et al. CAR‐NK cell in cancer immunotherapy; A promising frontier
JP2024074801A5 (https=)
Kershaw et al. Gene-engineered T cells for cancer therapy
Fan et al. Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia
JP2017523784A5 (https=)
US11970545B2 (en) T cell-antigen coupler with Y182T mutation and methods of uses thereof
US10654934B2 (en) Use of chimeric antigen receptor modified cells to treat cancer
JP2017531687A5 (https=)
RU2017114174A (ru) Композиции и способы для бустинга эффективности адоптивной клеточной иммунотерапии
JP2021512637A5 (https=)
JP2022527267A5 (https=)
JP2022525099A5 (https=)
BR112021000735A2 (pt) acoplador de antígeno de células t com várias otimizações de construto
JP2022523971A5 (https=)
JP2022523553A5 (https=)
JP2022547809A5 (https=)
JP2021525067A5 (https=)
WO2018064921A1 (en) Use of chimeric antigen receptor modified cells to treat cancer
JP2022543059A5 (https=)
Hanagiri et al. Retracted: Antitumor activity of human γδ T cells transducted with CD 8 and with T‐cell receptors of tumor‐specific cytotoxic T lymphocytes
JP2022543058A5 (https=)
Smith et al. Immunotherapy of colorectal cancer
JP2022543060A5 (https=)
Smith Jr et al. Targeting cancer with genetically engineered TCR T cells